Summary of Pulmonx (LUNG) Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $21.5 million, a 5% increase year-over-year from $20.4 million.

U.S. Revenue: $14 million, a modest 1% increase from $13.8 million in the prior year.

International Revenue: $7.5 million, a 15% increase compared to $6.6 million last year.

Gross Margin: Approximately 75%, up from 74% year-over-year.

Operating Expenses: $30.4 million, a 4% increase from $29.2 million in Q3 2024.

Net Loss: $14 million, or $0.34 per share, compared to a net loss of $14.1 million, or $0.36 per share, in the prior year.

Cash Position: $76.5 million in cash and cash equivalents, down $7.7 million from Q2 2025.

2Strategic Updates and Business Highlights

Glen French has returned as CEO, with Derrick Sung as COO and CFO, both emphasizing a focus on value creation and operational efficiency.

Pulmonx has established a market-leading position with its Zephyr Valves, which are recognized as the standard of care for severe emphysema.

The company has a strong commercial infrastructure with a significant global sales force and established reimbursement pathways in the U.S. and other markets.

Plans to improve execution and align spending with growth expectations, focusing on profitable growth and extending cash runway.

3Forward Guidance and Outlook

Full Year 2025 Revenue Guidance: Revised to $89 million to $90 million.

Gross Margin Guidance: Expected to be approximately 73% for the full year.

Operating Expense Guidance: Projected to be between $125 million and $126 million, including about $21 million in noncash stock-based compensation.

4Challenges and Points of Concern

U.S. Growth Deceleration: Sales growth in the U.S. has slowed, raising concerns about the effectiveness of recent investments.

Operating Leverage Issues: The company has struggled to achieve operating leverage, impacting profitability.

Cash Utilization: Total cash utilization for the first three quarters of 2025 was approximately $25 million, necessitating a focus on extending the cash runway.

Underperforming Territories: There are disparities in performance across different regions, with some areas not meeting growth expectations.

5Notable Q&A Insights

Management acknowledged the complexity of the patient referral process and emphasized the need for efficiency in moving patients through treatment.

Glen French indicated that while there is optimism about improving underperforming territories, specific details on strategies will be provided in future calls.

Derrick Sung clarified that extending the cash runway involves reallocating expenses to more productive areas rather than seeking external financing.

Both executives highlighted the importance of focusing on high-impact initiatives and avoiding speculation on future strategies until they have more data. Overall, Pulmonx is navigating a challenging environment with a focus on improving execution and profitability while addressing growth concerns, particularly in the U.S. market.